Biotechnology News and Research

RSS

Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN

Mayo Clinic has licensed patent rights from QIAGEN to enable Mayo Medical Laboratories to offer an M. tuberculosis complex speciation test. The test expands Mayo Medical Laboratories' current offering for tuberculosis testing, which already includes M. tuberculosis complex culture, molecular identification and drug susceptibility testing.

From QIAGEN Manchester Limited 19 Jul 2011

Sherpa opens new CGMP production facility in San Diego

Sherpa Clinical Packaging, a privately held provider of Clinical Trial Material management services, hosted a ribbon cutting ceremony today to mark the opening of its newly constructed state-of-the-art, CGMP production facility in San Diego, CA.

19 Jul 2011

U.S. Patent Office issues Notice of Allowance for Kuros' PTH to improve bone healing

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has received Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office.

19 Jul 2011

Nano-patterned plastic to advance stem cell research

Scientists have developed a novel plastic surface which overcomes the difficulties associated with growing adult stem cells. Standard surfaces have proved limited for growing large amounts and retaining the stem cells' useful characteristics. This discovery could lead to the creation of stem cell therapies for re-growing bone and tissue, and also for conditions such as arthritis. The study was carried out by Glasgow and Southampton universities.

18 Jul 2011

Two existing clinical stage clients expand development activities with Progenitor Cell Therapy

Progenitor Cell Therapy (PCT), an internationally recognized cell therapy services and development company, and a wholly-owned subsidiary of NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that two existing clinical stage biopharmaceutical corporate clients have chosen to expand their development activities with PCT.

18 Jul 2011

Scientists use two methods to manipulate disease-causing mutations in stem cells

Using two distinct methods, Whitehead Institute researchers have successfully and consistently manipulated targeted genes in both human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells.

16 Jul 2011

Teva, Amgen settle G-CSF patent litigation

Amgen announced today that the United States (U.S.) District Court in Pennsylvania has entered final judgment and a permanent injunction against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA prohibiting them from infringing Amgen's patents relating to human G-CSF and methods for its use.

16 Jul 2011

Champions Oncology revenue increases 41% to $6.9 million for fiscal 2011

For its fiscal year 2011, Champions generated revenue of $6.9 million, an increase of $2 million or 41%, compared to fiscal year 2010.

16 Jul 2011

FDA ODAC recommends approval of Seattle Genetics' ADCETRIS for Hodgkin lymphoma after ASCT

Seattle Genetics, Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10-0 to recommend that the FDA grant accelerated approval of ADCETRIS™ (brentuximab vedotin) for the treatment of patients with Hodgkin lymphoma who relapse after autologous stem cell transplant (ASCT).

15 Jul 2011

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen today announced that the European Commission (EC) has granted marketing authorization for XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors.

15 Jul 2011

Nuvilex to move International Corporate HQ near FDA headquarters

Nuvilex, Inc. announced today it is in the final stages of locating its International Corporate Headquarters near the headquarters of the U.S. Food and Drug Administration.

15 Jul 2011

Seattle Children's inaugurates new center for cancer research

Today, Seattle Children's Research Institute announced the opening of the Center for Childhood Cancer Research.

15 Jul 2011

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint.

15 Jul 2011

Camel blood can help scientists fight against cancer

Nanobodies produced from camel blood have unique properties, which can be used in future drug development. New research published in Journal of Controlled Release confirms that camel blood can help scientists in the fight against cancer.

15 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

ICON announces acquisition of Firecrest Clinical

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of Firecrest Clinical, a market-leading provider of technology solutions that boost investigator site performance and study management.

14 Jul 2011

inVentiv Health announces completion of PharmaNet acquisition

inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced it has completed the acquisition of PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries.

14 Jul 2011

Two promising projects focus on new treatments for cystic fibrosis

Two promising projects have been selected to undergo preclinical testing as part of the Cystic Fibrosis Technology Initiative.

14 Jul 2011

Mary Ann Liebert launches new journal on games, human health

Mary Ann Liebert, Inc. announces the launch of Games for Health: Research, Development, and Clinical Applications (G4H), a new, peer-reviewed journal dedicated to the development, use, and applications of game technology for improving physical and mental health and well-being.

14 Jul 2011

RXi expands intellectual property portfolio with additional NeuVax patents

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax.

14 Jul 2011